Escitalopram in the treatment of generalized anxiety disorder

References

• Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, WA, USA (2000).
   Google Scholar
• Carter RM, Wittchen HU, Pfister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress. Anxiety 13, 78–88 (2001).
   PubMed Web of Science ®Google Scholar
• Wittchen HU. Generalized anxiety disorder: prevalence, burden and cost to society. Depress. Anxiety 16, 162–171 (2002).
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Carter RM, Pfister H et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int. Clin. Psychopharmacol. 13, 319–328 (2000).
   Google Scholar
• Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br. J. Psychiatry 176, 544–549 (2000).
   PubMed Web of Science ®Google Scholar
• Beekman AT, Bremmer MA, Deeg DJ et al. Anxiety disorders in late life: a report from the Longitudinal Aging Study Amsterdam. Int. J. Geriatr. Psychiatry 13, 717–726 (1998).
   PubMed Web of Science ®Google Scholar
• Kessler RC, DuPont RL, Berglund et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry 156, 1915–1923 (1999).
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Sisitsky T, Kessler RC et al. The economic burden of anxiety disorders in the 1990s. J. Clin. Psychiatry 60, 427–435 (1999).
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JRT. Generalized anxiety disorder: neurobiologic and pharmacotherapeutic perspectives. Biol. Psychiatry 44, 1286–1294 (1998).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biologic Psychiatry (WFSBP) guidelines for the pharmacologic treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psychiatry 3, 171–199 (2002).
   PubMedGoogle Scholar
• Allgulander C, Bandelow B, Hollander E et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectrums 8, 53–61 (2003).
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Management of anxiety (panic disorder, with or without agoraphobia, and generalized anxiety disorder) in adults in primary, secondary and community care. National Institute for Clinical Excellence, London, UK (2004).
   Google Scholar
• Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int. J. Neuropsychopharmacol. (2005).
   Google Scholar
• Kapczinski F, Schmitt R, Lima MS. The use of antidepressants for generalized anxiety disorder. Cochrane Database Syst. Rev. (2003).
   Google Scholar
• Mendels J, Krajewski TF, Huffer V et al. Effective short-term treatment of anxiety: a double-blind trial. J. Clin. Psychiatry 47, 170–174 (1986).
   PubMed Web of Science ®Google Scholar
• Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 139, 402–406 (1998).
   PubMed Web of Science ®Google Scholar
• Llorca PM, Sapdone C, Sol O et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a three-month double-blind study. J. Clin. Psychiatry 63, 1020–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 23, 240–249 (2003).
   PubMed Web of Science ®Google Scholar
• Moller HJ, Volz HP, Reimann IW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J. Clin. Psychopharmacol.21, 59–65 (2001).
   PubMed Web of Science ®Google Scholar
• Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR. Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J. Clin. Psychiatry84, 355–358 (1987).
   Google Scholar
• Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J. Clin. Psychiatry 62, 523–39 (2001).
   PubMed Web of Science ®Google Scholar
• Rickels K, Zaninelli R, McCafferty JP et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry 160, 749–756 (2003).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder: twenty-four week placebo-controlled dose-ranging study. Br. J. Psychiatry 179, 15–22 (2001).
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Sheehan DV et al. Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. Am. J. Psychiatry 157, 968–974 (2000).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Dahl AA, Austin C et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am. J. Psychiatry 161, 1642–1649 (2004)
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J. Psychiatric. Res. 36, 209–217 (2002).
   PubMed Web of Science ®Google Scholar
• Stocchi FG, Nordera G, Jokinen RH et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry 64, 250–258 (2003).
   PubMed Web of Science ®Google Scholar
• Gould RA, Otto MW, Pollack MH et al. Cognitive behavioral and pharmacologic treatment of generalised anxiety disorder: a preliminary meta-analysis. Behav. Ther. 28, 285–305 (1997).
   Web of Science ®Google Scholar
• Fisher PL, Durham RC. Recovery rates in generalized anxiety disorder following psychologic therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol. Med. 29, 1425–1434 (1999).
   PubMed Web of Science ®Google Scholar
• Lader MH, Bond AJ. Interaction of pharmacologic and psychologic treatments of anxiety. Br. J. Psychiatry 173(Suppl. 34), 42–48 (1998).
   Google Scholar
• Power KG, Simpson RJ, Swanson V et al. Controlled comparison of pharmacologic and psychologic treatment of generalized anxiety disorder in primary care. Br. J. Gen. Pract. 40, 289–294 (1990).
   PubMed Web of Science ®Google Scholar
• Durham RC, Turvey AA. Cognitive therapy versus behavior therapy in the treatment of chronic generalised anxiety. Behav. Res. Ther. 25, 229–234 (1987).
   PubMed Web of Science ®Google Scholar
• Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 50, 345–350 (2001).
   PubMed Web of Science ®Google Scholar
• Sanchez S, Bergqvist PBF, Brennum LT et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects of animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167, 353–362 (2003).
   PubMed Web of Science ®Google Scholar
• Mørk A, Kreilgard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced release in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45, 167–173 (2003).
   PubMed Web of Science ®Google Scholar
• Drewes P, Thijssen I, Mengel H. A single-dose, cross-over pharmacokinetic study comparing racemic citalopram (40 mg) with the S-enantiomer of citalopram (escitalopram, 20 mg) in healthy male volunteers. Poster presented at the 41st Annual Meeting of the New Clinical Data Evaluation Unit (NCDEU). Phoenix, AZ, USA, May 29 – June 1 (2001).
   Google Scholar
• Von Moltke LL, Greenblatt DJ, Giancarlo GM et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. 29, 1102–1109 (2001).
   PubMed Web of Science ®Google Scholar
• Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram. Br. J. Clin. Pharmacology (2005) (In Press).
   Google Scholar
• Joffe P, Larsen FS, Pedersen V et al. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur. J. Clin. Pharmacology 54, 237–242, (1998).
   PubMed Web of Science ®Google Scholar
• Areberg J, Christophersen JS, Poulsen MN et al. The pharmacokinetics of escitalopram in subjects with hepatic impairment. Nord. J. Psychiatry (2005) (In Press).
   Google Scholar
• Davidson JRT, Bose A, Korotzer A et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo-controlled, flexible-dose study. Depress. Anxiety 19, 234–240 (2004).
   PubMed Web of Science ®Google Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J. Affect. Disord. (2005) (In Press).
   Google Scholar
• Stein D, Andersen HF, Goodman W. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann. Clin. Psych. (2005) (In Press).
   Google Scholar
• Baldwin DS, Huusom AKT, Maehlum E. Escitalopram and paroxetine compared to placebo in generalised anxiety disorder. Eur. Neuropsychopharmacol. 14(Suppl. 3), S311–S312 (2004).
   Google Scholar
• Davidson JRT, Bose A, Nil R, Wang Q. Long term treatment of generalized anxiety disorder with escitalopram. Eur. Psychiatry 19(Suppl. 1), S224 (2004).
   Google Scholar
• Bielski R, Bose A, Nil R, Chang CC. Double-blind comparison of escitalopram and paroxetine in the treatment of generalized anxiety disorder. Eur. Psychiatry 19(Suppl. 1), S223 (2004).
   Google Scholar
• Allgulander C, Huusom AKT, Florea I. Escitalopram for relapse prevention in generalized anxiety disorder (GAD). Nord. J. Psychiatry (2005) (In Press).
   Google Scholar
• Baldwin DS, Thompson CV. The future of antidepressant pharmacotherapy. World Psychiatry2, 3–8 (2003).
   Google Scholar
• Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nature Rev. Drug Discov. 3, 136–151 (2004).
   PubMed Web of Science ®Google Scholar
• Haynes RB, Devereaux PJ, Guyatt GH. Physicians’ and patients’ choices in evidence based practice. Br. Med. J. 324, 1350 (2002).
   PubMed Web of Science ®Google Scholar